公开(公告)号：US10323038B2

公开(公告)日：2019-06-18

申请号：US15777201

申请日：2016-11-18

Applicant: ABIDE THERAPEUTICS, INC.

Inventor： Cheryl A. Grice ,  Todd K. Jones ,  Katharine K. Duncan ,  Justin S. Cisar ,  Jeffrey E. Merit ,  Olivia D. Weber

IPC: C07D487/10 ,  C07D487/04 ,  C07D471/10 ,  C07D519/00 ,  C07D403/06 ,  C07D491/08 ,  C07D231/40 ,  C07D231/38 ,  C07D403/12 ,  C07D417/12 ,  C07D401/12 ,  C07D413/12 ,  C07D498/08

Abstract: Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or FAAH. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain.

公开(公告)号：US10030020B2

公开(公告)日：2018-07-24

申请号：US15593239

申请日：2017-05-11

Applicant: Abide Therapeutics, Inc.

Inventor： Justin S. Cisar ,  Cheryl A. Grice ,  Todd K. Jones ,  Olivia D. Weber ,  Daniel J. Buzard ,  Michael B. Shaghafi

IPC: C07D471/10 ,  C07D519/00

Abstract: Provided herein are spirocycle compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

公开(公告)号：US09994537B2

公开(公告)日：2018-06-12

申请号：US15672165

申请日：2017-08-08

Applicant: Abide Therapeutics, Inc.

Inventor： Justin S. Cisar ,  Cheryl A. Grice ,  Todd K. Jones ,  Olivia D. Weber ,  Dong-Hui Wang

IPC: C07D295/205 ,  C07D207/08 ,  C07D471/10 ,  C07D417/04 ,  C07D403/04 ,  C07D401/04 ,  C07D295/26 ,  C07D265/30 ,  C07D207/12 ,  C07D211/38 ,  C07D211/58 ,  C07D207/14 ,  C07D211/14 ,  C07D498/08 ,  C07D211/62 ,  C07D487/04 ,  C07D207/16

CPC classification number: C07D295/205 ,  C07D207/08 ,  C07D207/12 ,  C07D207/14 ,  C07D207/16 ,  C07D211/14 ,  C07D211/38 ,  C07D211/58 ,  C07D211/62 ,  C07D265/30 ,  C07D295/26 ,  C07D401/04 ,  C07D403/04 ,  C07D417/04 ,  C07D471/10 ,  C07D487/04 ,  C07D498/08

Abstract: Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

公开(公告)号：US09981930B1

公开(公告)日：2018-05-29

申请号：US15814318

申请日：2017-11-15

Applicant: ABIDE THERAPEUTICS, INC.

Inventor： Cheryl A. Grice ,  Donald L. Hertzog ,  Daniel J. Buzard ,  Nicole S. White

IPC: C07D295/205 ,  C07B59/00

CPC classification number: C07D295/205 ,  C07B59/002 ,  C07B2200/05

Abstract: Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

公开(公告)号：US09133148B2

公开(公告)日：2015-09-15

申请号：US14599105

申请日：2015-01-16

Applicant: Abide Therapeutics, Inc. ,  The Scripps Research Institute

Inventor： Justin S. Cisar ,  Cheryl A. Grice ,  Todd K. Jones ,  Micah J. Niphakis ,  Jae Won Chang ,  Kenneth M. Lum ,  Benjamin F. Cravatt

IPC: A61K31/495 ,  A61K31/496 ,  C07D207/09 ,  C07D207/14 ,  C07D213/56 ,  C07D205/04 ,  C07D295/26 ,  C07D295/205 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D405/14 ,  C07D215/42 ,  C07D213/40 ,  C07C271/12 ,  C07D317/46 ,  C07D317/58 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D241/04 ,  C07D471/04 ,  C07D471/10 ,  C07D261/08 ,  C07D263/32 ,  C07D271/06 ,  C07D307/79 ,  C07D213/55 ,  C07D401/04 ,  C07D407/06 ,  C07D413/06 ,  C07C271/10

CPC classification number: C07D295/205 ,  C07C271/10 ,  C07C271/12 ,  C07D205/04 ,  C07D207/09 ,  C07D207/14 ,  C07D213/38 ,  C07D213/40 ,  C07D213/55 ,  C07D215/42 ,  C07D215/46 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D241/04 ,  C07D261/08 ,  C07D263/32 ,  C07D271/06 ,  C07D295/26 ,  C07D307/79 ,  C07D317/46 ,  C07D317/58 ,  C07D401/04 ,  C07D401/10 ,  C07D403/10 ,  C07D405/14 ,  C07D407/06 ,  C07D413/06 ,  C07D413/10 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107

Abstract: This disclosure provides piperazine carbamates and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed piperazine carbamates as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.

Abstract translation: 本公开提供哌嗪类氨基甲酸酯和可以是MAGL和/或ABHD6的调节剂的组合物及其作为药物的用途，其制备方法和包括公开的哌嗪氨基甲酸酯作为至少一种活性剂的药物组合物。 本公开还提供了治疗有需要的患者的方法，其中患者患有诸如疼痛，实体瘤癌症和/或肥胖的适应症，其包括施用所公开的化合物或组合物。

公开(公告)号：US20210363105A1

公开(公告)日：2021-11-25

申请号：US17338182

申请日：2021-06-03

Applicant: Celgene Corporation ,  Abide Therapeutics, Inc.

Inventor： Lianfeng Huang ,  Nancy Tsou ,  Nicole Suzanne White ,  Jun Xu ,  Qun Zhang

IPC: C07D211/94 ,  A61P35/00

Abstract: Provided herein are crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate. Pharmaceutical compositions comprising crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate are also disclosed.

公开(公告)号：US11129827B2

公开(公告)日：2021-09-28

申请号：US16431632

申请日：2019-06-04

Applicant: Abide Therapeutics, Inc.

Inventor： Cheryl A. Grice ,  Justin S. Cisar ,  Katharine K. Duncan ,  Yu Feng ,  John J. M. Wiener ,  Olivia D. Weber

IPC: A61K31/496 ,  A61K31/506 ,  A61P25/04

Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds useful as modulators of MAGL and/or FAAH. The subject compounds and compositions are useful for the treatment of pain and neurological disorders.

公开(公告)号：US11053199B2

公开(公告)日：2021-07-06

申请号：US16569578

申请日：2019-09-12

Applicant: Celgene Corporation ,  Abide Therapeutics, Inc.

Inventor： Lianfeng Huang ,  Nancy Tsou ,  Nicole Suzanne White ,  Jun Xu ,  Qun Zhang

IPC: C07D211/94 ,  A61P35/00

Abstract: Provided herein are crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate. Pharmaceutical compositions comprising crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate are also disclosed.

公开(公告)号：US20200022977A1

公开(公告)日：2020-01-23

申请号：US16300501

申请日：2017-05-11

Applicant: ABIDE THERA, INC.

Inventor： Daniel J. BUZARD ,  Michael B. SHAGHAFI ,  Justin S. CISAR ,  Cheryl A. GRICE ,  Todd K. JONES ,  Olivia D. WEBER

IPC: A61K31/499 ,  A61K31/541 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/55

Abstract: Provided herein are spirocycle compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

公开(公告)号：US09957242B2

公开(公告)日：2018-05-01

申请号：US15272313

申请日：2016-09-21

Applicant: Abide Therapeutics, Inc. ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： Justin S. Cisar ,  Cheryl A. Grice ,  Todd K. Jones ,  Micah J. Niphakis ,  Jae Won Chang ,  Kenneth M Lum ,  Benjamin F. Cravatt

IPC: C07D213/55 ,  C07D231/12 ,  C07D261/08 ,  A61K31/496 ,  C07D295/205 ,  C07D405/14 ,  C07D215/42 ,  C07D213/40 ,  C07C271/12 ,  C07D317/46 ,  C07D317/58 ,  C07D231/16 ,  C07D231/56 ,  C07D241/04 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D263/32 ,  C07D205/04 ,  C07D491/107 ,  C07D207/14 ,  C07D271/06 ,  C07D295/26 ,  C07D307/79 ,  C07D401/04 ,  C07D407/06 ,  C07D413/06 ,  C07C271/10 ,  C07D207/09 ,  C07D213/38 ,  C07D215/46 ,  C07D401/10 ,  C07D403/10 ,  C07D413/10

CPC classification number: C07D295/205 ,  C07C271/10 ,  C07C271/12 ,  C07D205/04 ,  C07D207/09 ,  C07D207/14 ,  C07D213/38 ,  C07D213/40 ,  C07D213/55 ,  C07D215/42 ,  C07D215/46 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D241/04 ,  C07D261/08 ,  C07D263/32 ,  C07D271/06 ,  C07D295/26 ,  C07D307/79 ,  C07D317/46 ,  C07D317/58 ,  C07D401/04 ,  C07D401/10 ,  C07D403/10 ,  C07D405/14 ,  C07D407/06 ,  C07D413/06 ,  C07D413/10 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107

Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.